Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Replacing all regular meals with a low calorie diet of soups, shakes and bars, together with behavioural support, is cost-effective as a routine treatment for obesity, according to researchers from the University of Oxford.

The droplet study infographic

Published today in the journal Obesity, the study is the first to estimate the long term health benefit and builds on the results of the DROPLET trial1, which showed that ‘total diet replacement’ programmes (TDRs) are a safe and effective way to lose weight, with significant weight loss persisting to at least 12 months.

Nearly two thirds of adults in England are overweight or obese, increasing the risk of life-altering illnesses, such as type 2 diabetes, heart disease, stroke, and some cancers.

The NHS recently announced a pilot programme to offer a TDR programme to around 5,000 people with type 2 diabetes and has also committed to offering weight loss support for people with hypertension who are also obese.

Read more (NIHR CLAHRC Oxford website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.